These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 22544183)

  • 21. Global Fund pulls grants from mismanaging countries.
    Wakabi W
    CMAJ; 2007 Jan; 176(3):311-2. PubMed ID: 17261822
    [No Abstract]   [Full Text] [Related]  

  • 22. The Global Fund's resource allocation decisions for HIV programmes: addressing those in need.
    Avdeeva O; Lazarus JV; Aziz MA; Atun R
    J Int AIDS Soc; 2011 Oct; 14():51. PubMed ID: 22029667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Global Fund-supported programmes contribution to international targets and the Millennium Development Goals: an initial analysis.
    Komatsu R; Low-Beer D; Schwartländer B
    Bull World Health Organ; 2007 Oct; 85(10):805-11. PubMed ID: 18038063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The obligation to provide antiretroviral treatment in HIV prevention trials.
    Lo B; Padian N; Barnes M
    AIDS; 2007 Jun; 21(10):1229-31. PubMed ID: 17545698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Global Fund Round 11 cancellation fiasco: turning disaster into opportunity?
    Zumla A
    Int J Tuberc Lung Dis; 2012; 16(3):285-6. PubMed ID: 22640440
    [No Abstract]   [Full Text] [Related]  

  • 26. Generic HIV drugs--enlightened policy for global health.
    Wainberg MA
    N Engl J Med; 2005 Feb; 352(8):747-50. PubMed ID: 15728804
    [No Abstract]   [Full Text] [Related]  

  • 27. Civil society organisations and global health initiatives: problems of legitimacy.
    Doyle C; Patel P
    Soc Sci Med; 2008 May; 66(9):1928-38. PubMed ID: 18291566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Brazilian experiment: HIV drugs for all.
    Flaer PJ; Younis MZ
    J Health Care Finance; 2009; 36(2):90-6. PubMed ID: 20499725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Donor support for quality assurance and pharmacovigilance of anti-malarials in malaria-endemic countries.
    Kovacs SD; Mills BM; Stergachis A
    Malar J; 2017 Jul; 16(1):282. PubMed ID: 28693488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A critical analysis of Peru's HIV grant proposals to the Global Fund.
    Cáceres CF; Amaya AB; Sandoval C; Valverde R
    Glob Public Health; 2013; 8(10):1123-37. PubMed ID: 24329168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Access to antiretroviral treatment in developing countries: Which financing strategies are possible?
    Beaulière A; Le Maux A; Trehin C; Perez F
    Rev Epidemiol Sante Publique; 2010 Jun; 58(3):171-9. PubMed ID: 20430553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Funding. Global Fund approves $850 million in grants over 5 years.
    AIDS Policy Law; 2006 Nov; 21(21):2. PubMed ID: 17153235
    [No Abstract]   [Full Text] [Related]  

  • 33. Global health initiative investments and health systems strengthening: a content analysis of global fund investments.
    Warren AE; Wyss K; Shakarishvili G; Atun R; de Savigny D
    Global Health; 2013 Jul; 9(1):30. PubMed ID: 23889824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surveillance of transmitted HIV drug resistance in the Manzini-Mbabane corridor, Swaziland, in 2006.
    Maphalala G; Okello V; Mndzebele S; Gwebu P; Mulima N; Dlamini S; Nhlabatsi B; Ginindza T; Ghebrenegus Y; Ntilivamunda A; Mwanyumba F; Ledwaba J; Pillay V; Bennett DE
    Antivir Ther; 2008; 13 Suppl 2():95-100. PubMed ID: 18575197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV drug resistance threshold survey using specimens from voluntary counselling and testing sites in Hanoi, Vietnam.
    Nguyen HT; Duc NB; Shrivastava R; Tran TH; Nguyen TA; Thang PH; McNicholl JM; Leelawiwat W; Chonwattana W; Sidibe K; Fujita M; Luu CM; Kakkar R; Bennett DE; Kaplan J; Cosimi L; Wolfe MI
    Antivir Ther; 2008; 13 Suppl 2():115-21. PubMed ID: 18575200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Performance-based financing at the Global Fund to Fight AIDS, Tuberculosis and Malaria: an analysis of grant ratings and funding, 2003-12.
    Fan VY; Duran D; Silverman R; Glassman A
    Lancet Glob Health; 2013 Sep; 1(3):e161-8. PubMed ID: 25104264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Asia can afford universal access for AIDS prevention and treatment.
    Komatsu R; McLeod R; Sarkar S; Siripong N; Gupta I; Tangcharoensathien V; Brown T; Jeugmans J; Avila-Figueroa C; Atun R
    AIDS; 2010 Sep; 24 Suppl 3():S72-9. PubMed ID: 20926931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Critical interactions between Global Fund-supported programmes and health systems: a case study in Indonesia.
    Desai M; Rudge JW; Adisasmito W; Mounier-Jack S; Coker R
    Health Policy Plan; 2010 Nov; 25 Suppl 1():i43-47. PubMed ID: 20966109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in Addis Ababa, Ethiopia.
    Abegaz WE; Grossman Z; Wolday D; Ram D; Kaplan J; Sibide K; Wuhib T; Ismael S; Nkengasong J; Mekonen T; Berhanu H; Messele T; Lulseged S; Maayan S; Mengistu Y
    Antivir Ther; 2008; 13 Suppl 2():89-94. PubMed ID: 18575196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacovigilance and global HIV/AIDS.
    Miller V; Nwokike J; Stergachis A
    Curr Opin HIV AIDS; 2012 Jul; 7(4):299-304. PubMed ID: 22627711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.